Anal Cancer - Pipeline Review, H1 2012

Anal Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Anal Cancer - Pipeline Review, H1 2012', provides an overview of the Anal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Anal Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anal Cancer . 'Anal Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anal Cancer .
- A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anal Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anal Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Anal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Anal Cancer Therapeutic Products under Development, Key Players in Anal Cancer Therapeutics, Anal Cancer Pipeline Overview, Anal Cancer Pipeline, Anal Cancer Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Anal Cancer
Anal Cancer Therapeutics under Development by Companies
Anal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Anal Cancer Therapeutics – Products under Development by Companies
Anal Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Anal Cancer Therapeutics Development
PDS Biotechnology Corporation
Anal Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PDS0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Fluorouracil + Mitomycin C + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Fluorouracil + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Interleukin-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xeloda + Eloxatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Cetuximab + Cisplatin + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitomycin + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isotretinoin + Interferon Alfa-2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Fluoroucacil + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-Fluorouracil + Mitomycin C + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 + Mitomycin C + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vorinostat + Paclitaxel + Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vectibix + Mitomicin C + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MTS-01 + 5-Fluorouracil + Mitomycin-C + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P16_37-63 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anal Cancer Therapeutics - Dormant Products
Anal Cancer – Product Development Milestones
Featured News & Press Releases
Jan 19, 2012: National Advisory Committee On Immunization Recommends Merck's GARDASIL
Apr 06, 2011: U.S. Prescribing Information for GARDASIL Updated; Indication Not Granted for Use in Adult Women
Feb 02, 2011: Merck Announces New England Journal Of Medicine Publishes Efficacy And Safety Data For GARDASIL In Males
Dec 22, 2010: US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL
Nov 17, 2010: Merck Announces FDA Advisory Committee Supports Approval Of GARDASIL For Prevention Of Anal Cancer And AIN
Oct 16, 2009: FDA Approves GARDASIL for Use in Boys and Young Men
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Anal Cancer, H1 2012
Products under Development for Anal Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
PDS Biotechnology Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Anal Cancer Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Anal Cancer, H1 2012
Products under Development for Anal Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012